Follows people with liver cancer treated with tremelimumab and durvalumab
Observes adults with advanced liver cancer receiving tremelimumab plus durvalumab.
Plain-language title generated from the registry record
Registry title: MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Key facts
- Where
- Ancona, Bergamo, Foggia, Meldola, Milan, Modena, Naples, Padova, Palermo, Pisa, Pozzuoli, Roma, Rozzano, Torino, and Verona, ItalySee the 15 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07607769, who can take part
Where in Italy
- AnconaAncona, ItalyNo longer taking part
- BergamoBergamo, ItalyTaking people
- FoggiaFoggia, ItalyTaking people
- MeldolaMeldola, ItalyTaking people
- MilanMilan, ItalyNo longer taking part
- ModenaModena, ItalyNo longer taking part
- NaplesNaples, ItalyTaking people
- PadovaPadova, ItalyTaking people
- PalermoPalermo, ItalyTaking people
- PisaPisa, ItalyTaking people
- PozzuoliPozzuoli, ItalyNo longer taking part
- RomaRoma, ItalyTaking people
- RozzanoRozzano, ItalyNo longer taking part
- TorinoTorino, ItalyNo longer taking part
- VeronaVerona, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07607769
- Record updated
- 29 September 2026
- Original description
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment.Read full original descriptionShow less
MONTEROSA Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment. (Real World Observational Study of STRIDE Regimen for Advanced HCC)
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic treatment.
Inclusion: - Signed informed consent; Age ≥ 18 years; Histologically or radiologically confirmed diagnosis of advanced or unresectable HCC; BCLC B or C HCC; Child-Pugh A (score 5 or 6); Eastern Cooperative Oncology Group (ECOG) Performance Status score 0 or 1; Planned first-line treatment of advanced/uHCC with STRIDE.
Exclusion: - Any previous line of systemic therapy for HCC; Any prior or concomitant immunotherapy; Prior allogeneic organ or bone marrow transplant; Documented active or previous GI bleeding within the previous 12 months; Autoimmune disease requiring treatment with immunosuppressive medication; Main trunk portal vein thrombosis; Known hypersensitivity to the active substance or to any of the STRIDE excipients; Pregnancy or breastfeeding.